Can't Handle the Itch? Refractory Immunotherapy-related Transient Acantholytic Dermatosis: Prompt Resolution with Dupilumab

Overview

Journal JAAD Case Rep

Specialty Dermatology

Date 2022 Mar 11

PMID 35274032

Authors

Eva Shelton

Coley Doolittle

Michi M Shinohara

John A Thompson

Ata S Moshiri

Affiliations

Soon will be listed here.

Citing Articles

ERK hyperactivation in epidermal keratinocytes impairs intercellular adhesion and drives Grover disease pathology.

Simpson C, Tiwaa A, Zaver S, Johnson C, Chu E, Harms P JCI Insight. 2024; 9(21).

PMID: 39325541 PMC: 11601706. DOI: 10.1172/jci.insight.182983.

Grover's Disease Association with Cutaneous Keratinocyte Cancers: More than a Coincidence?.

Nedelcu R, Dobre A, Turcu G, Andrei R, Balasescu E, Pantelimon F Int J Mol Sci. 2024; 25(17).

PMID: 39273660 PMC: 11395229. DOI: 10.3390/ijms25179713.

Pumping the Breaks on Acantholytic Skin Disorders: Targeting Calcium Pumps, Desmosomes, and Downstream Signaling in Darier, Hailey-Hailey, and Grover Disease.

Harmon R, Ayers J, McCarthy E, Kowalczyk A, Green K, Simpson C J Invest Dermatol. 2024; 145(3):494-508.

PMID: 39207315 PMC: 11846705. DOI: 10.1016/j.jid.2024.06.1289.

The Use of Biologic Agents for the Treatment of Cutaneous Immune-Related Adverse Events from Immune Checkpoint Inhibitors: A Review of Reported Cases.

Pach J, Valido K, Belzer A, Leventhal J Am J Clin Dermatol. 2024; 25(4):595-607.

PMID: 38767827 DOI: 10.1007/s40257-024-00866-z.

Dupilumab in Inflammatory Skin Diseases: A Systematic Review.

Olbrich H, Sadik C, Ludwig R, Thaci D, Boch K Biomolecules. 2023; 13(4).

PMID: 37189381 PMC: 10136243. DOI: 10.3390/biom13040634.

References

Kaye A, Gordon S, Deverapalli S, Her M, Rosmarin D . Dupilumab for the Treatment of Recalcitrant Bullous Pemphigoid. JAMA Dermatol. 2018; 154(10):1225-1226. DOI: 10.1001/jamadermatol.2018.2526. View

Gangwar R, Friedman S, Seaf M, Levi-Schaffer F . Mast cells and eosinophils in allergy: Close friends or just neighbors. Eur J Pharmacol. 2015; 778:77-83. DOI: 10.1016/j.ejphar.2015.10.036. View

Gordon S, Robinson S, Abudu M, Her M, Deverapalli S, Levin A . Eosinophilic annular erythema treated with dupilumab. Pediatr Dermatol. 2018; 35(4):e255-e256. DOI: 10.1111/pde.13533. View

Russo R, Cozzani E, Gasparini G, Parodi A . Targeting interleukin 4 receptor α: A new approach to the treatment of cutaneous autoimmune bullous diseases?. Dermatol Ther. 2019; 33(1):e13190. PMC: 7154653. DOI: 10.1111/dth.13190. View

Maloney N, Tegtmeyer K, Zhao J, Worswick S . Dupilumab in Dermatology: Potential for Uses Beyond Atopic Dermatitis. J Drugs Dermatol. 2019; 18(10). View

Chen W, Tetzlaff M, Diwan H, Jahan-Tigh R, Diab A, Nelson K . Suprabasal acantholytic dermatologic toxicities associated checkpoint inhibitor therapy: A spectrum of immune reactions from paraneoplastic pemphigus-like to Grover-like lesions. J Cutan Pathol. 2018; 45(10):764-773. DOI: 10.1111/cup.13312. View

Chan L, Robinson N, Xu L . Expression of interleukin-4 in the epidermis of transgenic mice results in a pruritic inflammatory skin disease: an experimental animal model to study atopic dermatitis. J Invest Dermatol. 2001; 117(4):977-83. DOI: 10.1046/j.0022-202x.2001.01484.x. View

Sehra S, Yao Y, Howell M, Nguyen E, Kansas G, Leung D . IL-4 regulates skin homeostasis and the predisposition toward allergic skin inflammation. J Immunol. 2010; 184(6):3186-90. PMC: 2837507. DOI: 10.4049/jimmunol.0901860. View

Hardy-Werbin M, Rocha P, Arpi O, Taus A, Nonell L, Duran X . Serum cytokine levels as predictive biomarkers of benefit from ipilimumab in small cell lung cancer. Oncoimmunology. 2019; 8(6):e1593810. PMC: 6492977. DOI: 10.1080/2162402X.2019.1593810. View

10.

Myklebust J, Irish J, Brody J, Czerwinski D, Houot R, Kohrt H . High PD-1 expression and suppressed cytokine signaling distinguish T cells infiltrating follicular lymphoma tumors from peripheral T cells. Blood. 2013; 121(8):1367-76. PMC: 3578953. DOI: 10.1182/blood-2012-04-421826. View

11.

Beer J, Rosenbach M . Grover Disease Associated With Chemotherapy: Review of Potential Pathophysiology, Current Treatments, and Future Directions. J Drugs Dermatol. 2020; 19(11):1056-1064. DOI: 10.36849/JDD.2020.5648. View

12.

Fishbein A, Silverberg J, Wilson E, Ong P . Update on Atopic Dermatitis: Diagnosis, Severity Assessment, and Treatment Selection. J Allergy Clin Immunol Pract. 2019; 8(1):91-101. PMC: 7395647. DOI: 10.1016/j.jaip.2019.06.044. View

13.

Cozzani E, Gasparini G, Di Zenzo G, Parodi A . Immunoglobulin E and bullous pemphigoid. Eur J Dermatol. 2018; 28(4):440-448. DOI: 10.1684/ejd.2018.3366. View

14.

Elbe-Burger A, Egyed A, Olt S, Klubal R, Mann U, Rappersberger K . Overexpression of IL-4 alters the homeostasis in the skin. J Invest Dermatol. 2002; 118(5):767-78. DOI: 10.1046/j.1523-1747.2002.01753.x. View

15.

Darrigade A, Legrand A, Andreu N, Jacquemin C, Boniface K, Taieb A . Dual efficacy of dupilumab in a patient with concomitant atopic dermatitis and alopecia areata. Br J Dermatol. 2018; 179(2):534-536. DOI: 10.1111/bjd.16711. View

16.

Khan M, Khan M, Aivaz O . Transient acantholytic dermatosis in a patient with prostate cancer. Dermatol Online J. 2020; 26(2). View

17.

Munoz J, Guillot B, Girard C, Dereure O, Du-Thanh A . First report of ipilimumab-induced Grover disease. Br J Dermatol. 2014; 171(5):1236-7. DOI: 10.1111/bjd.13058. View

18.

Oh C, Geba G, Molfino N . Investigational therapeutics targeting the IL-4/IL-13/STAT-6 pathway for the treatment of asthma. Eur Respir Rev. 2010; 19(115):46-54. PMC: 9491642. DOI: 10.1183/09059180.00007609. View

19.

Butler D, Kollhoff A, Berger T . Treatment of Grover Disease With Dupilumab. JAMA Dermatol. 2021; 157(3):353-356. DOI: 10.1001/jamadermatol.2020.5097. View